Tabs
FDA Center:
CBER
Study Type:
Protocol/Surveillance Plan
Assessment Type:
Safety Analyses
Population / Cohort:
All individuals 9-26 years of age
Data Sources:
Mini-Sentinel Distributed Database (MSDD)
Workgroup Leader(s):
Katherine Yih, PhD, MPH; Judith Maro, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Adamma Mba-Jonas, MD; Laura Polakowski, MD; Jane Woo, MD; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Workgroup Members:
Meghan Baker, MD, ScD; Carolyn Balsbaugh, MPH; Elizabeth Cavagnaro, MPH; Claudia Coronel-Moreno, MPH; Sandra Feibelmann, MPH; Grace Lee, MD, MPH; Lingling Li, PhD; Ryan Saliga; Lauren Zichittella, MS; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Azadeh Shoaibi, MS, MHS, PhD; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD